Form 4: Supernus Pharmaceuticals Executive Granted Stock Options and Restricted Stock Units

Padmanabh P. Bhatt, a Senior VP at Supernus Pharmaceuticals, received stock options and restricted stock units on February 19, 2025.

Summary

• Padmanabh P. Bhatt, a Senior VP of IP and CSO at Supernus Pharmaceuticals, was granted stock options and restricted stock units.
• On February 19, 2025, Bhatt acquired 20,000 stock options with an exercise price of $33.52.
• These options vest in four equal annual installments starting February 19, 2026, and expire on February 19, 2035.
• Bhatt also acquired 4,500 restricted stock units (RSUs) on the same date.
• These RSUs vest in four equal annual installments beginning February 19, 2026, and are settled in common stock upon vesting.
• Following these transactions, Bhatt directly owns 10,149 shares of common stock, 20,000 stock options, and 4,500 restricted stock units.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, which are generally viewed favorably as aligning management and shareholder interests.

Positives

• The grant of stock options and restricted stock units aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock options and restricted stock units are common forms of executive compensation in the pharmaceutical industry, used to incentivize performance and retain key personnel. This grant is consistent with industry practices.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice in the pharmaceutical industry to align management's interests with shareholder value.
• Companies like Biogen, Amgen, and Gilead Sciences also utilize similar equity-based compensation plans for their executives.
• The vesting schedules and exercise prices are generally benchmarked against peer companies to ensure competitiveness and retention.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align executive compensation with company performance.
• Employees may see this as a positive sign of the company investing in its leadership.

Key Dates